|
|
|
|
|
Last Trade
|
Last Trade:
$73.61
|
Change:
0.47 (0.64%)
|
Trade Time:
Nov 25
|
Market Cap:
$1.24B
|
|
|
|
|
|
|
Description of Business
|
|
We are a biopharmaceutical company focused on developing or acquiring
technologies that help pharmaceutical companies discover and develop medicines.
We employ research technologies such as antibody discovery technologies, ion
channel discovery technology, Pseudomonas fluorescens protein expression
technology, formulation science and liver targeted pro-drug technologies to
assist companies in their work toward securing prescription drug and biologic
approvals. We currently have partnerships and license agreements with over 140
pharmaceutical and biotechnology companies. Over 400 programs are in various
stages of commercialization, development or research and are fully funded by our
collaboration partners and licensees. We have contributed novel research and
technologies for approved medicines that treat cancer, osteoporosis, fungal
infections and postpartum depression, among others.
|
|
|
|